EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

α-Bisabolol alleviates doxorubicin-induced cognitive dysfunction in rats via enhancing the hippocampal BDNF/TrKB signaling and inhibiting neuroinflammation

Sara T Elazab, Walter H Hsu

Frontiers in Pharmacology · 07.03.2025 · 16

DOI: 10.3389/fphar.2025.1549009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 07.03.2025. Verfasst von Sara T Elazab und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Veterinary Medicine, Mansoura University, Mansoura, Egypt. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemofog is a serious sequela commonly manifested among cancer patients receiving doxorubicin (DOX) chemotherapy. Our goal was to explore the abrogative action of α-Bisabolol (BISA), a phytochemical sesquiterpene, against DOX-induced cognitive deficit. Rats were allocated into 5 groups: Group I: control; Group II received BISA orally (100 mg/kg/day for 4 weeks); Group III received DOX (2 mg/kg/week/i.p.) for 4 weeks; Groups IV and V were administered BISA orally at 50 and 100 mg/kg, respectively plus DOX, i. p. Results: 1) BISA attenuated DOX-induced chemofog as shown in memory-related behavioral tests. 2) BISA restored the hippocampal histological structure and redox homeostasis via diminishing MDA content and upregulating Nrf2 and HO-1 genes. 3) BISA mitigated DOX-induced neuroinflammation through reducing NF-kB, TNF-α, IL-6, IL-1β, and GFAP expressions. 4) BISA repressed the hippocampal apoptosis via downregulating Bax gene and upregulating Bcl-2 gene. 5) BISA enhanced the synaptic plasticity by activating the BDNF/TrKB signaling and increasing the levels of neurotransmitters that enhance memory, i.e., ACh, 5-HT, and DA. BISA at 100 mg/kg/day exerted a better neuroprotection than BISA at 50 mg/kg/day. Thus, BISA may protect cancer patients from cognitive disorders caused by DOX.

Schlagwörter

Stichwörter der Autor:innen

BDNF/TrKB signalingchemobraincognitive impairmentdoxorubicinoxidative stressα-bisabolol

Autor:innen und Institutionen

  • Department of Pharmacology, Faculty of Veterinary Medicine, Mansoura University, Mansoura, Egypt.
  • Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA, United States.

Zitieren

APA

Elazab, S. T., & Hsu, W. H. (2025). α-Bisabolol alleviates doxorubicin-induced cognitive dysfunction in rats via enhancing the hippocampal BDNF/TrKB signaling and inhibiting neuroinflammation. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1549009

Vancouver

Elazab ST, Hsu WH. α-Bisabolol alleviates doxorubicin-induced cognitive dysfunction in rats via enhancing the hippocampal BDNF/TrKB signaling and inhibiting neuroinflammation. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1549009

BibTeX
@article{Elazab2025,
  author = {Elazab, Sara T and Hsu, Walter H},
  title = {α-Bisabolol alleviates doxorubicin-induced cognitive dysfunction in rats via enhancing the hippocampal BDNF/TrKB signaling and inhibiting neuroinflammation},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1549009}
}
Kostenlos starten →